Skip to content
Screener

Mannkind MNKD Insulin — Purchase Obligation

Similar metrics at other companies

Roku, Inc. logo
ROKUOther obligations — Purchase Obligation
$322.15M+119%
Roku, Inc. logo
ROKUContent — Purchase Obligation
$133.88M-29.0%
Roku, Inc. logo
ROKUManufacturing — Purchase Obligation
$484.84M+185%
WEC Energy Group logo
WECElectric — Purchase Obligation
$5.05B-11.2%
WEC Energy Group logo
WECNatural gas — Purchase Obligation
$2.92B+19.3%
Sphere Entertainment logo
SPHRMSG Networks — Purchase Obligation
$43.04M

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.32B+25.9%
Enterprise value$1.28B+27.4%
P/S3.4×-0.1×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:PurchaseObligation.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054

The Company periodically reviews the terms of the long-term Insulin Supply Agreement and assesses the need for any accrual for estimated losses, such as lower-of-cost or net-realizable-value that will not be recovered by future product sales. The recognized loss on purchase commitments of $64.1 million and $66.0 million is included in our condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively, and is reduced as inventory items are received or such liability is extinguished.

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's insulin — purchase obligation?
Mannkind (MNKD) reported insulin — purchase obligation of $64.1M in Q2 2026.
How has Mannkind's insulin — purchase obligation changed year-over-year?
Mannkind's insulin — purchase obligation decreased by 3.0% year-over-year, from $66.1M to $64.1M.
What is the long-term trend for Mannkind's insulin — purchase obligation?
Over 3 years (2021 to 2025), Mannkind's insulin — purchase obligation has grown at a -9.2% compound annual growth rate (CAGR), from $345.9M to $258.8M.
What does insulin — purchase obligation mean?
This metric represents the total future financial commitments the company is contractually obligated to pay for goods or services related to the insulin product line. It reflects the long-term liability associated with supply chain agreements and manufacturing capacity requirements. Investors use this to assess the company's fixed cost structure and potential liquidity pressure arising from non-cancellable supply contracts.

Ask your AI about Mannkind's insulin — purchase obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude